Nivolumab Trial
Phase 2
40
about 13 years
12+
1 site in MD
About this study
Researchers are testing if Nivolumab can slow the growth of certain cancers, specifically Epstein-Barr Virus (EBV)-positive lymphoproliferative disorders and EBV-positive non-Hodgkin lymphomas. The trial will evaluate the safety of this treatment in adults and children with these conditions who have not responded to other therapies.
Based on ClinicalTrials.gov records.
What participants do
- 1.Receive Nivolumab
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
nivolumab (Immune checkpoint inhibitor; blocks PD-1 receptor on T cells)
infusion
Primary: overall response rate of nivolumab in patients with EBV-positive LPD and EBV-positive NHL
Secondary: PFS of patients with EBV-LPD treated with nivolumab, overall survival of patients with EBV-LPD treated with nivolumab, toxicity profile of nivolumab in patients with EBV-LPD
Oncology